GLP-1 medications work by mimicking a hormone your body naturally produces after eating. They slow gastric emptying, increase satiety signals to the brain, improve insulin response, and reduce glucagon output — four mechanisms that together lower appetite and stabilise blood glucose. Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP), which is the mechanistic difference that separates the two most-studied drugs in the class. The class was originally developed for type 2 diabetes and later approved for chronic weight management; research into cardiovascular, cognitive, and metabolic applications is ongoing.
What GLP-1 actually is
GLP-1 — glucagon-like peptide-1 — is a hormone your body produces naturally. It's released by specialised cells in the small intestine (L-cells) in response to eating, particularly after meals containing carbohydrates and fats.
Native GLP-1 has a short half-life. It's released, does its work, and is broken down by an enzyme called DPP-4 within minutes. Its natural role is to help the body respond appropriately to food: signal fullness to the brain, tell the pancreas to release insulin, tell the stomach to slow down, and moderate the release of glucagon (the hormone that raises blood sugar between meals).
In healthy metabolic function, this system operates in the background. In insulin resistance, type 2 diabetes, and obesity, the GLP-1 signalling pathway is often blunted — the hormone is released, but the body's response is weaker than it should be. This is the physiological problem GLP-1 receptor agonist medications were designed to address.
How the medications mimic the natural hormone
GLP-1 receptor agonists are synthetic molecules engineered to bind to the same receptors as native GLP-1, produce the same downstream effects, but stay in the body far longer. Where native GLP-1 has a half-life measured in minutes, the newer generation of GLP-1 medications has a half-life measured in days — long enough to support once-weekly dosing.
The molecules are structurally similar to native GLP-1 but modified in specific positions to resist enzymatic degradation. This is why they persist long enough to produce sustained effects rather than the transient signal the native hormone produces.
Two of the most-studied medications in this class are semaglutide (marketed under the brand names Ozempic for type 2 diabetes and Wegovy for chronic weight management) and tirzepatide (marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management). Both are approved by the FDA. Both are administered by weekly subcutaneous injection.
Semaglutide vs tirzepatide: the mechanistic difference
The most important pharmacological distinction between the two is receptor selectivity.
Semaglutide is a selective GLP-1 receptor agonist. It binds to and activates one receptor: the GLP-1 receptor. Everything it does — appetite reduction, delayed gastric emptying, improved insulin response, reduced glucagon — flows from that single receptor engagement.
Tirzepatide is a dual agonist. It activates the GLP-1 receptor and also activates the GIP receptor. GIP (glucose-dependent insulinotropic polypeptide) is another gut hormone released after eating. It has its own effects on insulin secretion, fat metabolism, and — the area of active research — appetite regulation.
The clinical significance is that tirzepatide's dual mechanism has produced, in head-to-head trials of the branded products, larger average reductions in body weight than semaglutide over the same duration. Whether the difference comes primarily from the additional GIP activity, from tirzepatide's pharmacokinetics, or from both, is still being characterised in the literature.
The next generation of the class — triple agonists activating GLP-1, GIP, and glucagon receptors simultaneously — is now in late-stage clinical trials.
The four mechanisms behind the effect
The weight and metabolic effects of GLP-1 receptor agonists come from four distinct mechanisms operating together:
1. Central appetite regulation. GLP-1 receptors are present in areas of the brain involved in appetite and satiety — including the hypothalamus and brainstem. Activation of these receptors reduces hunger signals and increases the sensation of fullness. Patients on these medications typically report feeling satisfied with substantially smaller portions and experiencing less spontaneous food-seeking behaviour.
2. Delayed gastric emptying. GLP-1 slows the rate at which the stomach empties food into the small intestine. This extends the physical sensation of fullness after meals and slows the rate at which glucose enters the bloodstream from a meal — smoothing out the post-meal glucose spike.
3. Glucose-dependent insulin release. GLP-1 stimulates the pancreas to release insulin in response to elevated blood glucose. The "glucose-dependent" part matters: unlike some older diabetes medications, GLP-1 agonists don't drive insulin release when glucose is already low, which is why they carry a lower risk of hypoglycaemia when used on their own.
4. Reduced glucagon release. Glucagon is the hormone that raises blood sugar by signalling the liver to release stored glucose. GLP-1 suppresses inappropriate glucagon release, particularly after meals, contributing to more stable blood glucose overall.
The combined effect of these four mechanisms is what produces the outcomes the class is known for: reduced appetite, reduced caloric intake, improved glycaemic control, and — over time — significant reductions in body weight in the populations these medications are studied in.
What the clinical evidence has shown
The evidence base for GLP-1 receptor agonists is one of the largest for any recent drug class. Multiple large randomised controlled trials, published in peer-reviewed journals, have documented the effects of the branded formulations in populations with type 2 diabetes and obesity.
The STEP trials (semaglutide) and SURMOUNT trials (tirzepatide) are the largest and most-cited studies. Both trial programmes reported meaningful average reductions in body weight over 68–72 weeks of treatment, alongside improvements in glycaemic control, blood pressure, and lipid markers. Cardiovascular outcome trials (SUSTAIN-6 for semaglutide, SURPASS-CVOT for tirzepatide) have looked at longer-term effects on cardiovascular events.
Two important framing points on the evidence:
First, the trial data is for the specific FDA-approved branded products, at specific doses, in specific patient populations, over specific durations. Individual response varies considerably. Average trial outcomes are not predictions for any individual patient.
Second, the class is a treatment, not a cure. The clinical trials tested the medications while patients were taking them. What happens after stopping is a different question, addressed further down.
What the class is being studied for beyond weight
Research into GLP-1 receptor agonists has expanded well beyond diabetes and weight management. Active areas of clinical investigation include:
Cardiovascular disease. Studies have reported reductions in major adverse cardiovascular events in populations with diabetes and established cardiovascular disease, prompting interest in the class's cardioprotective effects.
Kidney disease. Trials are examining slowing of chronic kidney disease progression in populations with type 2 diabetes.
Neurodegenerative disease. GLP-1 receptors are present in the brain, and early-stage research is exploring the class's role in conditions including Parkinson's disease and Alzheimer's disease.
Addiction and reward pathways. Observational reports and early research suggest the class may reduce cravings for alcohol, nicotine, and other reward-linked behaviours — an area currently under formal investigation.
Fatty liver disease. Research is examining effects on MASH (metabolic dysfunction-associated steatohepatitis), with promising early results.
These are research directions, not approved indications. The applications above are not what patients receive the class for today. But the breadth of the research pipeline explains why GLP-1 biology has become one of the most active areas of drug development.
What happens when the medication stops
This is the question the clinical trials have started to answer and where the field's understanding is still developing.
When the medication is stopped, the pharmacological signalling stops with it. The delayed gastric emptying reverses. The appetite suppression fades. Insulin and glucagon responses return to whatever they were before treatment. This is not a failure of the medication — it's the direct consequence of removing an active pharmacological input.
Extension studies of the STEP programme (specifically STEP-4) have documented that a substantial portion of the weight lost during semaglutide treatment tends to return when the medication is discontinued. This has reshaped how clinicians think about the class — not as a short-term intervention but as a longer-term treatment for a chronic condition, similar to how blood pressure or cholesterol medications are typically used.
For patients considering GLP-1 medication, this reality matters. The mechanism is powerful while it's active. The clinical decision isn't just whether to start — it's what the sustained protocol, exit strategy, and follow-up look like over the years ahead. That's the conversation to have with a clinician before starting, not after.
Medical disclaimer
This article is general education, not medical advice, and is not a recommendation for any specific medication. Consult with a licensed healthcare provider to determine what treatment is appropriate for you.
Clinically reviewed by
Amelia Baweja
